combination with cytotoxic chemotherapies. 1 In January 2008, trastuzumab was approved for use as single-agent therapy after standard adjuvant chemotherapy for early-stage, HER2-positive breast cancer, independent of nodal status, based on data from the
Search Results
Huei-Ting Tsai, Claudine Isaacs, Filipa C. Lynce, Suzanne C. O'Neill, Chunfu Liu, Marc D. Schwartz, Nandini Selvam, Yingjun Zhou, and Arnold L. Potosky
Presenter: Smitha S. Krishnamurthi
variability in the risk of recurrence in early-stage colon cancer. Ideally, we’d like to identify who has been cured by surgery, who will be cured with adjuvant chemotherapy, and who will not benefit from chemotherapy,” she said. “Prognostic and predictive
Kshama Jaiswal, Madelyne Hull, Anna L. Furniss, Reina Doyle, Natalia Gayou, and Elizabeth Bayliss
patients have a median time of 69 days to starting RT after their last surgery when no other adjuvant chemotherapy was indicated. The process of external referral to radiation oncology adds significantly to the delay (median of 22 days from referral to
Robert W. Carlson and on behalf of the NCCN Breast Cancer Panel
axillary lymph nodes; and, to a lesser extent, presence or absence of estrogen receptor (ER) and progesterone receptor (PR). In this paradigm, clinicians estimated the risk of recurrence and, if it was large enough, provided adjuvant chemotherapy and—if the
Robert J. Motzer, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Mark K. Buyyounouski, Michael A. Carducci, Sam S. Chang, Toni K. Choueiri, Shilpa Gupta, Steven L. Hancock, Gary R. Hudes, Eric Jonasch, Timothy M. Kuzel, Clayton Lau, Ellis G. Levine, Daniel W. Lin, Kim A. Margolin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Thomas W. Ratliff, Bruce G. Redman, Cary N. Robertson, Charles J. Ryan, Joel Sheinfeld, Jue Wang, and Richard B. Wilder
site of relapse in patients managed with surveillance or adjuvant chemotherapy is the retroperitoneal nodes. Chest radiographs may be obtained as clinically indicated for years 1 to 5. The clinical trial TRISST (MRC TE24/Trial of Imaging and Schedule in
Prajnan Das, Norio Fukami, and Jaffer A. Ajani
– 11 . 30. Earle CC Maroun JA . Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials . Eur J Cancer 1999 ; 35 : 1059 – 1064 . 31. Janunger KG
Stephen B. Edge
: a study of the National Comprehensive Cancer Network . Ann Surg 2006 ; 243 : 241 – 249 . 14. Brewster AM Etzel C Zhou R . The impact of obesity on receipt of adjuvant chemotherapy for breast cancer in the National Comprehensive Cancer
Jacob Klapper and Thomas A. D’Amico
immune system, and the superior compliance with adjuvant chemotherapy. Although the extent of the lymph node dissection that can be accomplished via VATS has been a matter of debate, the literature suggests equivalency. Watanabe et al 15 compared
Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, W. Bradford Carter, Stephen B. Edge, John K. Erban, William B. Farrar, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Mohammad Jahanzeb, Krystyna Kiel, Britt-Marie Ljung, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lisle M. Nabell, Lori J. Pierce, Elizabeth C. Reed, Mary Lou Smith, George Somlo, Richard L. Theriault, Neal S. Topham, John H. Ward, Eric P. Winer, and Antonio C. Wolff
adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15 . J Natl Cancer Inst 2000 ; 92 : 1991 – 1998 . 39 Piccart MJ Di Leo A Hamilton A . HER2 a ‘predictive factor’ ready to use in
Nadeem R. Abu-Rustum and Yukio Sonoda
based on the Intergroup trial, 17 as opposed to postoperative chemotherapy, is an intriguing question. In 1996, Curtin et al. 18 reported on the clinical efficacy of adjuvant chemotherapy alone versus chemotherapy plus whole pelvic radiation therapy
